PFS Investments’s Charles River Laboratories CRL Stock Holding History

PFS Investments’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$3.31M	Sell	15,739 -211	-1%	-$42K	0.05%	273
2023 Q1	$3.13M	Buy	15,950 +63	+0.4%	+$14.3K	0.05%	265
2022 Q4	$3.46M	Sell	15,887 -606	-4%	-$132K	0.06%	233
2022 Q3	$3.25M	Buy	16,493 +2,490	+18%	+$538K	0.06%	222
2022 Q2	$3M	Buy	14,003 +2,418	+21%	+$591K	0.06%	241
2022 Q1	$3.29M	Buy	11,585 +2,876	+33%	+$887K	0.06%	235
2021 Q4	$3.28M	Buy	+8,709	New	+$3.38M	0.06%	233

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

PFS Investments's CRL Position: Q2 2023 in Review

PFS Investments reduced its Charles River Laboratories (CRL) stake by 1.3% in Q2 2023, selling an estimated $42K and leaving 15,739 shares worth $3.31M. The position accounts for 0.05% of the portfolio, ranked #273.

PFS Investments first reported a position in CRL in Q4 2021 and has held it in 7 quarters since. The position peaked at $3.46M in Q4 2022. 611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

PFS Investments held 15,739 shares of Charles River Laboratories worth $3.31M as of Q2 2023.
PFS Investments sold 211 Charles River Laboratories shares in Q2 2023, an estimated $42K.
Charles River Laboratories made up 0.05% of PFS Investments's portfolio in Q2 2023, its #273 holding.
PFS Investments first reported a position in Charles River Laboratories in Q4 2021 and has held it in 7 quarters since.
PFS Investments's Charles River Laboratories position peaked at $3.46M in Q4 2022.
611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.